133 related articles for article (PubMed ID: 35131523)
1. Clinical Course and Unique Features of Silent Corticotroph Adenomas.
Huang L; Fatterpekar G; Charles S; Golub D; Zagzag D; Agrawal N
World Neurosurg; 2022 May; 161():e274-e281. PubMed ID: 35131523
[TBL] [Abstract][Full Text] [Related]
2. Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence.
Strickland BA; Shahrestani S; Briggs RG; Jackanich A; Tavakol S; Hurth K; Shiroishi MS; Liu CJ; Carmichael JD; Weiss M; Zada G
J Neurosurg; 2021 May; 135(6):1706-1713. PubMed ID: 33962375
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI.
Amano T; Masumoto T; Watanabe D; Hoshiai S; Mori K; Sakamoto N; Kino H; Akutsu H; Nakajima T
Jpn J Radiol; 2023 Sep; 41(9):938-946. PubMed ID: 37027094
[TBL] [Abstract][Full Text] [Related]
4. Silent corticotroph adenomas.
Cooper O
Pituitary; 2015 Apr; 18(2):225-31. PubMed ID: 25534889
[TBL] [Abstract][Full Text] [Related]
5. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.
Ioachimescu AG; Eiland L; Chhabra VS; Mastrogianakis GM; Schniederjan MJ; Brat D; Pileggi AV; Oyesiku NM
Neurosurgery; 2012 Aug; 71(2):296-303; discussion 304. PubMed ID: 22517250
[TBL] [Abstract][Full Text] [Related]
6. Silent corticotroph adenomas.
Ben-Shlomo A; Cooper O
Pituitary; 2018 Apr; 21(2):183-193. PubMed ID: 29344907
[TBL] [Abstract][Full Text] [Related]
7. Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.
Zhang K; Shou X; Chen H; Qiao N; He W; Chen Z; Shen M; Li S; Zhao Y; Zhang Z; Li Y; Ye H; Wang Y
Front Endocrinol (Lausanne); 2020; 11():608691. PubMed ID: 33584540
[TBL] [Abstract][Full Text] [Related]
8. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently.
Bradley KJ; Wass JA; Turner HE
Clin Endocrinol (Oxf); 2003 Jan; 58(1):59-64. PubMed ID: 12519413
[TBL] [Abstract][Full Text] [Related]
9. Clinical Parameters to Distinguish Silent Corticotroph Adenomas from Other Nonfunctioning Pituitary Adenomas.
Kim D; Ku CR; Park SH; Moon JH; Kim EH; Kim SH; Lee EJ
World Neurosurg; 2018 Jul; 115():e464-e471. PubMed ID: 29678704
[TBL] [Abstract][Full Text] [Related]
10. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.
Langlois F; Lim DST; Yedinak CG; Cetas I; McCartney S; Cetas J; Dogan A; Fleseriu M
Pituitary; 2018 Feb; 21(1):32-40. PubMed ID: 29032459
[TBL] [Abstract][Full Text] [Related]
11. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S
Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480
[TBL] [Abstract][Full Text] [Related]
12. A clinicoradiological analysis of silent corticotroph adenomas after the introduction of pituitary-specific transcription factors.
Goyal-Honavar A; Sarkar S; Asha HS; Kapoor N; Balakrishnan R; Vanjare H; Chacko G; Chacko AG
Acta Neurochir (Wien); 2021 Nov; 163(11):3143-3154. PubMed ID: 34181087
[TBL] [Abstract][Full Text] [Related]
13. Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system.
Jiang S; Zhu J; Feng M; Yao Y; Deng K; Xing B; Lian W; Wang R; Bao X
Pituitary; 2021 Aug; 24(4):564-573. PubMed ID: 33651318
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of silent corticotroph adenomas.
Alahmadi H; Lee D; Wilson JR; Hayhurst C; Mete O; Gentili F; Asa SL; Zadeh G
Acta Neurochir (Wien); 2012 Aug; 154(8):1493-8. PubMed ID: 22619024
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.
Jahangiri A; Wagner JR; Pekmezci M; Hiniker A; Chang EF; Kunwar S; Blevins L; Aghi MK
Neurosurgery; 2013 Jul; 73(1):8-17; discussion 17-8. PubMed ID: 23685641
[TBL] [Abstract][Full Text] [Related]
16. Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.
Rui W; Qiao N; Wu Y; Zhang Y; Aili A; Zhang Z; Ye H; Wang Y; Zhao Y; Yao Z
Eur Radiol; 2022 Mar; 32(3):1570-1578. PubMed ID: 34837512
[TBL] [Abstract][Full Text] [Related]
17. Radiomics model and clinical scale for the preoperative diagnosis of silent corticotroph adenomas.
Wang H; Chang J; Zhang W; Fang Y; Li S; Fan Y; Jiang S; Yao Y; Deng K; Lu L; Bao X; Feng F; Wang R; Feng M
J Endocrinol Invest; 2023 Sep; 46(9):1843-1854. PubMed ID: 37020103
[TBL] [Abstract][Full Text] [Related]
18. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
19. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas.
Nishioka H; Inoshita N; Mete O; Asa SL; Hayashi K; Takeshita A; Fukuhara N; Yamaguchi-Okada M; Takeuchi Y; Yamada S
Endocr Pathol; 2015 Dec; 26(4):349-55. PubMed ID: 26481628
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.
Cohen-Inbar O; Xu Z; Lee CC; Wu CC; Chytka T; Silva D; Sharma M; Radwan H; Grills IS; Nguyen B; Siddiqui Z; Mathieu D; Iorio-Morin C; Wolf A; Cifarelli CP; Cifarelli DT; Lunsford LD; Kondziolka D; Sheehan JP
J Neurooncol; 2017 Oct; 135(1):67-74. PubMed ID: 28913674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
